TFFP RSI Chart
Last 7 days
-17.9%
Last 30 days
2.5%
Last 90 days
-13.8%
Trailing 12 Months
784.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 479.8K | 785.1K | 932.3K | 733.9K |
2022 | 131.3K | 157.4K | 195.0K | 495.8K |
2021 | 0 | 0 | 0 | 88.2K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Aug 16, 2023 | carlson capital l p | sold | -391 | 0.3916 | -1,000 | - |
Aug 15, 2023 | rocamboli stephen | bought | 5,000 | 0.25 | 20,000 | - |
Aug 15, 2023 | coleman kirk allen | bought | 5,000 | 0.25 | 20,000 | chief financial officer |
Aug 15, 2023 | mills robert s | bought | 10,000 | 0.25 | 40,000 | - |
Aug 15, 2023 | mikhak zamaneh | bought | 30,000 | 0.25 | 120,000 | chief medical officer |
Aug 15, 2023 | carlson capital l p | sold | -94,041 | 0.4374 | -215,000 | - |
Aug 15, 2023 | roberts brandi | bought | 5,000 | 0.25 | 20,000 | - |
Aug 15, 2023 | weisman harlan f | bought | 150,000 | 0.25 | 600,000 | president and ceo |
Mar 10, 2023 | rocamboli stephen | bought | 10,432 | 0.8025 | 13,000 | - |
Mar 10, 2023 | weisman harlan f | bought | 131,835 | 0.8789 | 150,000 | president and ceo |
Which funds bought or sold TFFP recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 11, 2024 | VANGUARD GROUP INC | sold off | -100 | -296,409 | - | -% |
Mar 11, 2024 | VANGUARD GROUP INC | new | - | 237,788 | 237,788 | -% |
Feb 28, 2024 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO | sold off | -100 | -8,000 | - | -% |
Feb 28, 2024 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO | new | - | 6,000 | 6,000 | -% |
Feb 26, 2024 | Virtu Financial LLC | sold off | -100 | -6,000 | - | -% |
Feb 16, 2024 | DRW Securities, LLC | sold off | -100 | -350,000 | - | -% |
Feb 16, 2024 | DRW Securities, LLC | new | - | 280,800 | 280,800 | -% |
Feb 14, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -878 | - | -% |
Feb 14, 2024 | GROUP ONE TRADING, L.P. | sold off | -100 | -483 | - | -% |
Feb 14, 2024 | STATE STREET CORP | sold off | -100 | -24,475 | - | -% |
Unveiling TFF Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to TFF Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 40.7B | 6.8B | -8.64 | 5.95 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.8B | 1.8B | -42.76 | 10.3 | ||||
BMRN | 16.5B | 2.4B | 98.3 | 6.81 | ||||
INCY | 12.8B | 3.7B | 21.4 | 3.46 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.41 | 17.87 | ||||
BBIO | 5.4B | - | -8.32 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.8 | 13.97 | ||||
ARWR | 3.5B | 240.7M | -11.94 | 14.72 | ||||
ACAD | 3.0B | 726.4M | -49.71 | 4.19 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.31 | 4.72 | ||||
NVAX | 669.0M | 983.7M | -1.23 | 0.68 | ||||
CRBP | 411.7M | 881.7K | -9.23 | 466.16 | ||||
INO | 324.4M | 4.9M | -2.4 | 66.66 | ||||
IBIO | 14.1M | 2.1M | -0.52 | 2.14 |
TFF Pharmaceuticals Inc News
Income Statement (Quarterly) | |||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 |
Revenue | -51.3% | 114 | 235 | 333 | 51.00 | 313 | 88.00 | 28.00 | 67.00 | 12.00 | 50.00 | 2.00 | 24.00 |
Operating Expenses | 17.8% | 5,483 | 4,655 | 5,352 | 7,138 | 7,694 | 7,368 | 8,780 | 8,451 | 10,108 | 8,728 | 5,113 | 7,926 |
S&GA Expenses | 10.6% | 2,509 | 2,269 | 2,670 | 3,119 | 3,560 | 3,342 | 3,678 | 3,213 | 3,188 | 2,388 | 2,351 | 2,647 |
R&D Expenses | 24.6% | 2,974 | 2,387 | 2,682 | - | 4,121 | 4,026 | 5,102 | 5,262 | 6,920 | 6,340 | 2,762 | 5,278 |
Interest Expenses | - | - | - | 36.00 | 35.00 | 8.00 | 6.00 | 6.00 | 7.00 | 10.00 | 12.00 | 14.00 | 15.00 |
Net Income | -8.0% | -4,762 | -4,409 | -5,020 | -7,051 | -7,373 | -7,274 | -8,746 | -8,376 | -10,049 | -8,678 | -4,655 | -7,654 |
Net Income Margin | -13.1% | -28.95* | -25.59* | -34.03* | -63.45* | -64.08* | -176.63* | -227.72* | -241.92* | -352.07* | - | - | - |
Free Cashflow | -43.4% | -4,284 | -2,988 | -4,599 | -4,506 | -7,843 | -8,156 | -5,509 | -7,383 | -11,010 | -7,333 | -6,014 | -6,067 |
Balance Sheet | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 | 2019Q3 | 2018Q4 |
Assets | -19.2% | 12.00 | 15.00 | 14.00 | 18.00 | 24.00 | 20.00 | 28.00 | 34.00 | 41.00 | 49.00 | 57.00 | 61.00 | 39.00 | 43.00 | 29.00 | 11.00 | 10.00 |
Current Assets | -30.3% | 8.00 | 11.00 | 9.00 | 14.00 | 19.00 | 17.00 | 25.00 | 32.00 | 39.00 | 47.00 | 55.00 | 60.00 | 38.00 | 42.00 | 29.00 | 11.00 | 10.00 |
Cash Equivalents | -43.5% | 5.00 | 10.00 | 8.00 | 12.00 | 17.00 | 13.00 | 21.00 | 26.00 | 34.00 | 45.00 | 52.00 | 58.00 | 35.00 | 42.00 | 28.00 | 11.00 | 10.00 |
Net PPE | -3.1% | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | - | - | - |
Liabilities | 106.0% | 2.00 | 1.00 | 1.00 | 2.00 | 1.00 | 2.00 | 4.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 2.00 | 2.00 | 2.00 | 1.00 |
Current Liabilities | 112.7% | 2.00 | 1.00 | 1.00 | 2.00 | 1.00 | 2.00 | 4.00 | - | 2.00 | - | - | - | 1.00 | 2.00 | 0.00 | - | 1.00 |
Shareholder's Equity | -30.1% | 10.00 | 14.00 | 12.00 | 17.00 | 23.00 | 18.00 | 24.00 | 32.00 | 39.00 | 48.00 | 56.00 | 60.00 | 37.00 | 42.00 | 28.00 | - | - |
Retained Earnings | -4.2% | -118 | -113 | -109 | -104 | -97.09 | -89.72 | -82.44 | -73.69 | -65.32 | -55.27 | -46.59 | -41.93 | -34.28 | -28.38 | -15.71 | -11.05 | -3.84 |
Additional Paid-In Capital | 0.5% | 128 | 127 | 122 | 121 | 120 | 108 | 106 | 105 | 104 | 103 | 102 | 102 | 72.00 | 70.00 | 43.00 | 0.00 | 1.00 |
Shares Outstanding | 0.2% | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | - | - | - | - |
Float | - | - | - | - | - | - | - | 139 | - | - | - | 229 | - | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -42.4% | -4,238 | -2,976 | -4,458 | -4,365 | -7,701 | -7,379 | -5,014 | -7,246 | -10,883 | -7,191 | -5,890 | -5,591 | -6,232 | -4,255 | -3,774 | -2,352 | -4,306 | -3,071 | -1,722 | -2,115 | - |
Share Based Compensation | -24.0% | 582 | 766 | 826 | 752 | 923 | 956 | 1,195 | 1,178 | 921 | 857 | 741 | 1,030 | 920 | 546 | 295 | 426 | 211 | -229 | 486 | 121 | - |
Cashflow From Investing | -266.7% | -46.39 | -12.65 | - | - | -141 | -777 | -495 | -137 | -126 | -141 | -124 | -476 | - | - | - | - | - | - | - | - | - |
Cashflow From Financing | -100.0% | 567* | 5,090 | -59.23 | -17.92 | 11,336 | 431 | - | - | - | - | 26.00 | 28,859 | 714 | - | - | - | 21,851 | -10.17 | - | - | - |
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Income Statement [Abstract] | ||||
Grant revenue | $ 234,763 | $ 87,586 | $ 619,543 | $ 183,025 |
Operating expenses: | ||||
Research and development | 2,386,707 | 4,025,940 | 9,087,264 | 14,360,293 |
General and administrative | 2,268,656 | 3,342,266 | 8,058,235 | 10,238,744 |
Total operating expenses | 4,655,363 | 7,368,206 | 17,145,499 | 24,599,037 |
Loss from operations | (4,420,600) | (7,280,620) | (16,525,956) | (24,416,012) |
Other income (expense): | ||||
Interest income | 88,810 | 6,119 | 160,009 | 19,184 |
Change in fair value of note receivable | (77,454) | (114,870) | ||
Total other income, net | 11,356 | 6,119 | 45,139 | 19,184 |
Net loss | $ (4,409,244) | $ (7,274,501) | $ (16,480,817) | $ (24,396,828) |
Net loss per share, basic (in Dollars per share) | $ (0.09) | $ (0.29) | $ (0.41) | $ (0.96) |
Weighted average common shares outstanding, basic (in Shares) | 47,441,693 | 25,451,691 | 39,983,825 | 25,399,352 |
Other comprehensive loss: | ||||
Foreign currency translation adjustments | $ (38,182) | $ (103,226) | $ (64,417) | $ (161,426) |
Comprehensive loss | $ (4,447,426) | $ (7,377,727) | $ (16,545,234) | $ (24,558,254) |
Condensed Consolidated Balance Sheets - USD ($) | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 9,725,755 | $ 16,612,315 |
Research and development tax incentive receivable | 361,485 | 186,507 |
Prepaid assets and other current assets | 805,659 | 2,226,344 |
Total current assets | 10,892,899 | 19,025,166 |
Operating lease right-of-use asset, net | 139,230 | 196,044 |
Property and equipment, net | 2,064,354 | 3,078,342 |
Note receivable - Augmenta | 1,781,000 | 1,812,975 |
Other assets | 7,688 | 7,688 |
Total assets | 14,885,171 | 24,120,215 |
Current liabilities: | ||
Accounts payable | 983,287 | 919,607 |
Accrued compensation | 4,430 | |
Deferred research grant revenue | 76,000 | 126,000 |
Current portion of operating lease liability | 82,725 | 80,625 |
Total current liabilities | 1,142,012 | 1,130,662 |
Operating lease liability, net of current portion | 52,230 | 110,094 |
Total liabilities | 1,194,242 | 1,240,756 |
Commitments and contingencies (see Note 4) | ||
Stockholders’ equity: | ||
Common stock; $0.001 par value, 90,000,000 shares and 45,000,000 shares authorized as of September 30, 2023 and December 31, 2022, respectively; 59,133,574 and 36,193,085 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | 59,134 | 36,193 |
Additional paid-in capital | 127,404,746 | 120,070,983 |
Accumulated other comprehensive loss | (203,712) | (139,295) |
Accumulated deficit | (113,569,239) | (97,088,422) |
Total stockholders’ equity | 13,690,929 | 22,879,459 |
Total liabilities and stockholders’ equity | $ 14,885,171 | $ 24,120,215 |